Difference between revisions of "Hoffmann M, et al, Cell (2020), cited as Ref 13 in DOI: 10.1007/s11886-020-01293-2 (Q11007)"
Jump to navigation
Jump to search
(Created claim: title (P93): SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. In vitro study demonstrating critical roles of ACE2 MPRSS2 in SARS-CoV-2 cell entry., #quickstat...) |
(Created claim: Publication Date (P100): 2020, #quickstatements; #temporary_batch_1592835264664) |
||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2020
| ||||||||||||||
| Property / Publication Date: 2020 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
Revision as of 14:15, 22 June 2020
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Hoffmann M, et al, Cell (2020), cited as Ref 13 in DOI: 10.1007/s11886-020-01293-2
|
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.
|
Statements
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. In vitro study demonstrating critical roles of ACE2 MPRSS2 in SARS-CoV-2 cell entry. (English)
0 references
2020
0 references
